Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMRF-56BDC-02
- Development stage
- Unknown
- Lead developer
- Mater Research
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
CMRF-56BDC-02 is an autologous blood dendritic cell (BDC) vaccine developed by the Mater Medical Research Institute for the treatment of metastatic castration-resistant (androgen-independent/hormone-refractory) prostate cancer. It is an autologous cellular immunotherapy that utilizes the chimeric monoclonal antibody hCMRF-56 to isolate primary blood dendritic cells from a patient's own blood. These dendritic cells are then loaded with tumor-associated antigen (specifically, in vitro transcribed mRNA encoding prostate cancer antigens) and administered back to the patient to induce antigen-specific cytotoxic T-lymphocyte (CTL) responses against prostate cancer cells. The vaccine was evaluated in a Phase 1 open-label, dose-finding clinical trial (ACTRN12607000451404) assessing its safety, tolerability, and preliminary immunologic and clinical activity.
- Other names
- CMRF-56+ blood dendritic cell vaccineCMRF-56+ BDC vaccineCMRF-56+ blood dendritic cell preparation
Beyond the preview
Go deeper on CMRF-56BDC-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMRF-56BDC-02.